Nls pharmaceutics announces the submission of three research abstracts to the 2025 ascp annual meeting

Zurich , jan. 30, 2025 /prnewswire/ --  nls pharmaceutics ltd. (nasdaq: nlsp) (nasdaq: nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (cns) disorders, is pleased to announce the submission of three research abstracts to the 2025 annual meeting of the american society of clinical psychopharmacology (ascp).
NLSP Ratings Summary
NLSP Quant Ranking